Cooperative Agreement U54CA295337
Award Date
9/20/24
Completion Date
8/31/29
Dollars Obligated
$1.3M
Federal Agency
National Cancer Institute
Awardee
Howard University (DYZNJGLTHMR9)
Federal Grant Program
93.397
Assistance Type
Cooperative Agreement
Place of Performance
Washington, DC 20059, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $2,688,546 Cooperative Agreement under the Cancer Centers Support Grants (CFDA 93.397) program to The Johns Hopkins University. The purpose of this 5-year award (effective 9/20/2024) is to establish a comprehensive cancer research, education, and outreach partnership between Johns Hopkins University and Howard University, focused on addressing cancer health disparities in the DC-Maryland-Virginia (DMV) region. The key objectives of this initiative,...
The U.S. National Cancer Institute (NCI) awarded a $3,024,739 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Southern California (USC) on July 23, 2024. The award, titled "Identifying Factors Associated with Prostate Cancer Progression and Survival in African American Men: The RESPOND Cohort", aims to understand the reasons for the higher incidence and mortality of prostate cancer among African American men. Over 5 years,...
The National Cancer Institute (NCI) awarded Emory University a $312,737 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program. The "Georgia Science Education Initiative NCI YES (GA-YES)" program aims to recruit and train high school students underrepresented in STEM careers, with a focus on rural and lower socioeconomic status students, in cancer research and disparities. Key program components include: 1) a summer mentored cancer research training...
The National Cancer Institute (NCI) awarded a $1,245,116 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to Emory University to enhance cervical cancer screening and treatment for women living with HIV in Kenya. The project, titled "ENHANCING CERVICAL CANCER SCREENING AND TREATMENT IN WOMEN LIVING WITH HIV IN KENYA (ENHANCE LINKAGE)", will adapt and test evidence-based implementation strategies to overcome barriers to integrating cervical...
The U.S. National Cancer Institute (NCI) awarded a $632,241 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to The Johns Hopkins University to leverage the existing HIV care infrastructure in Uganda to implement a comprehensive liver cancer control strategy, called the Liver Cancer Comprehensive Control (LC3) package. The LC3 package integrates the diagnosis and treatment of hepatitis B, primary prevention through adult vaccination, and referral for liver disease...
This $135,573 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support the following key objectives at the University of Virginia Comprehensive Cancer Center (UVA): Increase UVA's accrual depth and breadth in National Clinical Trials Network (NCTN) and Experimental Therapeutics Clinical Trials Network (ETCTN) clinical trials by identifying and overcoming provider and patient barriers. Increase UVA's leadership and collaboration in...
The National Cancer Institute (NCI) awarded a $3,998,962 Cooperative Agreement under the Cancer Cause and Prevention Research program (CFDA 93.393) to Northwestern University to establish the Advancing Cancer Control Equity Research Through Transformative Solutions in Patient Navigation (ACCERT PN) Center. The Center will develop community-engaged interventions, measures, and methods focused on innovative multilevel patient navigation approaches and implementation science within learning...
This federal Project Grant award of $334,233, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, will support a comprehensive research study examining disparities in novel cancer therapies, the joint effects of cancer treatment and comorbidities, and multi-level contributors to cancer survival outcomes. The University of South Carolina, the prime awardee, will conduct innovative data linkages between the state cancer registry,...
The National Cancer Institute (NCI) awarded a 5-year, $720,252 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA. The project, titled "Characterizing Genetic Risk of Cancer Across Diverse Populations Through Multi-Ancestry Epigenome Profiling and Chromatin QTL Discovery", aims to identify novel cancer risk-associated chromatin quantitative trait loci (cQTLs) in diverse, non-European ancestry...
The National Cancer Institute awarded a $118,687 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Florida to support the "STRONGER" program. This 5-year program (6/24/2025 - 5/31/2030) will provide 8 undergraduate students annually from non-R1 universities, including Historically Black Colleges and Universities and Hispanic-Serving Institutions, with hands-on cancer research internships. The interns will be paired with graduate student mentors...